NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ADXN

Addex Therapeutics Ltd ADR

Jul 03 • 01:30PM ET

9.38

Dollar change +0.24
Percentage change 2.68	%

Healthcare • Biotechnology • Switzerland • NASD

Peers: NBIX ACAD IONS SAGE LGND PTCT BHVN PRTA RIOT VTGN

Scroll to Statements

Index	-	P/E	2.16	EPS (ttm)	4.34	Insider Own	0.03%	Shs Outstand	0.82M	Perf Week	6.41%
Market Cap	7.69M	Forward P/E	-	EPS next Y	-5.84	Insider Trans	0.00%	Shs Float	0.82M	Perf Month	15.88%
Enterprise Value	4.55M	PEG	-	EPS next Q	-	Inst Own	1.60%	Short Float	0.27%	Perf Quarter	28.42%
Income	9.46M	P/S	27.46	EPS this Y	0.00%	Inst Trans	-78.28%	Short Ratio	0.23	Perf Half Y	17.19%
Sales	0.28M	P/B	0.82	EPS next Y	42.86%	ROA	-88.36%	Short Interest	0.00M	Perf YTD	33.93%
Book/sh	11.43	P/C	2.41	EPS next 5Y	-	ROE	-162.42%	52W High	13.27 -29.35%	Perf Year	5.10%
Cash/sh	3.89	P/FCF	-	EPS past 3/5Y	- -	ROIC	100.58%	52W Low	6.51 44.01%	Perf 3Y	-87.26%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-47.46% -30.40%	Gross Margin	-	Volatility	10.95% 9.27%	Perf 5Y	-
Dividend TTM	-	EV/Sales	16.24	EPS Y/Y TTM	164.35%	Oper. Margin	-1050.51%	ATR (14)	0.82	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.02	Sales Y/Y TTM	-82.24%	Profit Margin	3433.22%	RSI (14)	57.72	Recom	4.50
Dividend Gr. 3/5Y	- -	Current Ratio	3.02	EPS Q/Q	53.97%	SMA20	5.61%	Beta	1.65	Target Price	22.87
Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	-70.58%	SMA50	13.80%	Rel Volume	3.01	Prev Close	9.13
Employees	2	LT Debt/Eq	0.00	Earnings	Apr 25 BMO	SMA200	8.97%	Avg Volume	9.64K	Price	9.38
IPO	Jan 29, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	-89.15% -44.21%	Trades		Volume	28,993	Change	2.68%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-31-24	Upgrade	H.C. Wainwright	Neutral → Buy	$30

Jun-30-25 01:00AM	Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders (GlobeNewswire)
Jun-25-25 01:00AM	Addex Shareholders Approve All Resolutions at Annual General Meeting (GlobeNewswire)
Jun-19-25 01:00AM	Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-18-25 01:00AM	Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025 (GlobeNewswire)
Jun-06-25 01:00AM	Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models (GlobeNewswire) +19.33%
01:00AM	Loading…
Jun-05-25 01:00AM	Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference (GlobeNewswire) +5.08%
Jun-03-25 01:00AM	Addex Convenes Annual General Meeting 2025 (GlobeNewswire)
May-12-25 01:00AM	Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies (GlobeNewswire)
Apr-30-25 01:00AM	Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery (GlobeNewswire)
Apr-25-25 04:40PM	Addex Therapeutics Ltd (ADXN) Q4 2024 Earnings Call Transcript (Seeking Alpha) +7.37%
01:00AM	Addex Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-24-25 01:00AM	Addex Therapeutics to Release Full-Year 2024 Financial Results and Host Conference Call on April 25, 2025 (GlobeNewswire)
Apr-17-25 01:00AM	Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149 (GlobeNewswire)
Jan-08-25 01:00AM	Addex to Present at the 2025 Swiss Equities Baader Conference (GlobeNewswire)
Nov-22-24 01:00AM	Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -7.15%
01:00AM	Loading…
Nov-11-24 01:00AM	Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024 (GlobeNewswire)
Sep-30-24 01:00AM	Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire) +7.96%
Sep-19-24 01:00AM	Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit (GlobeNewswire)
Sep-04-24 01:00AM	Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -6.79%
Aug-27-24 01:00AM	Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration (GlobeNewswire) +51.17%
Jul-22-24 01:00AM	Addex's Partner Discontinues ADX71149 development in Epilepsy (GlobeNewswire)
Jul-15-24 01:00AM	Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS) (GlobeNewswire)
Jul-12-24 01:00AM	Addex To Present at the Thirteenth London International Cough Symposium (13th LICS) (GlobeNewswire)
Jul-01-24 01:00AM	Addex Shareholders Approve All Resolutions at Annual General Meeting (GlobeNewswire)
Jun-06-24 07:52AM	ADXN Stock Earnings: Addex Therapeutics Reported Results for Q1 2024 (InvestorPlace)
01:00AM	Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-05-24 01:00AM	Addex Convenes Annual General Meeting 2024 (GlobeNewswire)
May-31-24 01:00AM	Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024 (GlobeNewswire)
May-08-24 01:00AM	Addex to Present at Bio quity Europe 2024 (GlobeNewswire)
May-06-24 07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
07:31AM	Loading…
Apr-30-24 07:31AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Apr-29-24 07:33AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -53.17%
01:00AM	Addex Provides Update on ADX71149 Phase 2 Epilepsy Study (GlobeNewswire)
Apr-19-24 01:00AM	Addex to Present at the Swiss Biotech Day 2024 (GlobeNewswire)
Apr-18-24 06:52AM	ADXN Stock Earnings: Addex Therapeutics Reported Results for Q4 2023 (InvestorPlace)
01:00AM	Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-11-24 01:00AM	Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024 (GlobeNewswire)
Apr-03-24 01:00AM	Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders (GlobeNewswire) +16.35%
Mar-14-24 02:00AM	Addex to Present at the Bio-Europe Spring 2024 Conference (GlobeNewswire)
Jan-31-24 01:00AM	Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC. (GlobeNewswire)
Jan-09-24 01:00AM	Addex to Present at the Swiss Equities Baader Conference (GlobeNewswire)
Jan-05-24 01:30AM	Addex to Present at Biotech Showcase 2024 (GlobeNewswire) +6.69%
Dec-20-23 01:00AM	Addex Shareholders Approve All Resolutions at Extraordinary General Meeting (GlobeNewswire)
Dec-14-23 01:00AM	Addex Creates Treasury Shares (GlobeNewswire)
Nov-29-23 01:21AM	Addex Therapeutics Posts Narrower Loss In Q3 - Quick Facts (RTT News)
01:00AM	Addex Reports Q3 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-28-23 01:00AM	Addex Convenes Extraordinary General Meeting (GlobeNewswire)
Nov-23-23 01:00AM	Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023 (GlobeNewswire)
Nov-14-23 01:00AM	Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients (GlobeNewswire) +10.91%
Nov-08-23 01:00AM	Addex Regains Nasdaq Listing Compliance (GlobeNewswire)
Nov-02-23 02:00AM	Addex Announces Participation in the Bio-Europe 2023 Conference (GlobeNewswire) -11.67%
Oct-20-23 01:00AM	Addex Completes ADS Ratio Change (GlobeNewswire) -19.49%
Oct-06-23 04:00PM	Addex Announces Plan to Implement ADS Ratio Change (GlobeNewswire) +12.77% -9.07%
Oct-05-23 11:20AM	Addex Therapeutics focused on securing new partnerships to fund promising treatments (News Direct) +8.36%
Sep-20-23 01:00AM	Addex mGlu2 NAM Cognition Program Receives 4 Million Grant (GlobeNewswire)
Sep-06-23 01:00AM	Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -10.75%
Sep-05-23 01:00AM	Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024 (GlobeNewswire) +16.81%
Sep-04-23 01:00AM	Addexs Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain (GlobeNewswire)
Aug-10-23 01:00AM	Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-04-23 01:00AM	Addex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023 (GlobeNewswire)
Aug-03-23 01:00AM	Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration (GlobeNewswire)
Jul-24-23 01:00AM	Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder (GlobeNewswire)
Jun-15-23 01:00AM	Addex Increases Issued Share Capital to Create Treasury Shares (GlobeNewswire)
Jun-01-23 01:00AM	Addex Shareholders Approve All Resolutions at Annual General Meeting (GlobeNewswire) +7.67%
May-18-23 01:00AM	Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire)
May-11-23 01:00AM	Addex Reports Q1 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -5.70%
May-10-23 01:00AM	Addex Announces ADX71149 Phase 2 Epilepsy Clinical Studys Independent Interim Review Committee Recommends Continuing Study (GlobeNewswire) +26.27%
May-05-23 01:00AM	Addex Convenes Annual General Meeting 2023 (GlobeNewswire)
May-04-23 01:00AM	Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023 (GlobeNewswire)
Apr-05-23 01:00AM	Addex Completes $5.0 Million Equity Financing (GlobeNewswire) -18.07%
Apr-04-23 01:00AM	Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinsons Disease (GlobeNewswire) -7.09%
Apr-03-23 01:00AM	Addex Raises $5.0 Million in Equity Financing (GlobeNewswire) +5.02%
Mar-30-23 01:00AM	Addex Reports Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -14.16%
Mar-28-23 01:00AM	Addex Therapeutics to Release Full-Year 2022 Financial Results and Host Conference Call on March 30, 2023 (GlobeNewswire)
Mar-16-23 02:00AM	Addex Announces Upcoming Conferences it will participate for H1 2023 (GlobeNewswire) +10.45%
Feb-09-23 01:00AM	Addex Regains Nasdaq Listing Compliance (GlobeNewswire) +9.97%
Feb-06-23 01:00AM	Addex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1 (GlobeNewswire) -13.89%
Jan-19-23 01:00AM	Addex Provides Corporate Update and Financial Guidance (GlobeNewswire)
Dec-08-22 01:00AM	Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration (GlobeNewswire)
Nov-11-22 01:00AM	Addex Reports Q3 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-03-22 02:00AM	Addex Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 11, 2022 (GlobeNewswire)
02:00AM	Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire)
Nov-01-22 02:00AM	Addex Increases Issued Share Capital to Create Treasury Shares (GlobeNewswire) -5.88%
Sep-20-22 01:00AM	Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference (GlobeNewswire)
Aug-18-22 01:00AM	Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-15-22 01:00AM	Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders (GlobeNewswire)
Aug-12-22 01:00AM	Addex Therapeutics to Report Half-Year 2022 Financial Results and Host Conference Call on August 18, 2022 (GlobeNewswire)
Jul-26-22 04:00PM	Addex Completes $4.2 Million Equity Financing (GlobeNewswire) -6.34% -6.02%
Jul-22-22 01:00AM	Addex Raises $4.2 million in Equity Financing (GlobeNewswire)
Jul-21-22 01:00AM	Addex Provides Corporate Update and Financial Guidance (GlobeNewswire) +110.40%
01:00AM	Addex Completes Reduction in Nominal Value of Shares (GlobeNewswire)
Jun-17-22 01:00AM	Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinsons Disease due to Slow Recruitment Rate (GlobeNewswire) -55.16%
May-27-22 01:00AM	Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study (GlobeNewswire)
May-19-22 01:00AM	Addex Announces Participation in the H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-13-22 01:00AM	Addex Announces Participation in the 22nd Bioquity Europe Conference (GlobeNewswire)
May-10-22 01:00AM	Addex Shareholders Approve All Resolutions at Annual General Meeting (GlobeNewswire)
May-05-22 01:00AM	Addex Reports Q1 2022 Financial Results (GlobeNewswire) +7.93%
Apr-28-22 01:00AM	Addex to Present at the Swiss Biotech Day 2022 (GlobeNewswire) +7.28%
Apr-25-22 01:00AM	Addex to Present at the B. Riley Securities Neuro & Ophthalmology Virtual Investor Conference (GlobeNewswire) -11.38%
Apr-13-22 01:00AM	Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study (GlobeNewswire)

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ADXN

Addex Therapeutics Ltd ADR

Upgrade your FINVIZ experience